Cargando…
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383929/ https://www.ncbi.nlm.nih.gov/pubmed/28074071 http://dx.doi.org/10.1038/leu.2017.5 |
| _version_ | 1782520371284541440 |
|---|---|
| author | Ludwig, H Weisel, K Petrucci, M T Leleu, X Cafro, A M Garderet, L Leitgeb, C Foa, R Greil, R Yakoub-Agha, I Zboralski, D Vauléon, S Dümmler, T Beyer, D Kruschinski, A Riecke, K Baumann, M Engelhardt, M |
| author_facet | Ludwig, H Weisel, K Petrucci, M T Leleu, X Cafro, A M Garderet, L Leitgeb, C Foa, R Greil, R Yakoub-Agha, I Zboralski, D Vauléon, S Dümmler, T Beyer, D Kruschinski, A Riecke, K Baumann, M Engelhardt, M |
| author_sort | Ludwig, H |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5383929 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53839292017-04-23 Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study Ludwig, H Weisel, K Petrucci, M T Leleu, X Cafro, A M Garderet, L Leitgeb, C Foa, R Greil, R Yakoub-Agha, I Zboralski, D Vauléon, S Dümmler, T Beyer, D Kruschinski, A Riecke, K Baumann, M Engelhardt, M Leukemia Letter to the Editor Nature Publishing Group 2017-04 2017-02-03 /pmc/articles/PMC5383929/ /pubmed/28074071 http://dx.doi.org/10.1038/leu.2017.5 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spellingShingle | Letter to the Editor Ludwig, H Weisel, K Petrucci, M T Leleu, X Cafro, A M Garderet, L Leitgeb, C Foa, R Greil, R Yakoub-Agha, I Zboralski, D Vauléon, S Dümmler, T Beyer, D Kruschinski, A Riecke, K Baumann, M Engelhardt, M Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| title | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| title_full | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| title_fullStr | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| title_full_unstemmed | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| title_short | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| title_sort | olaptesed pegol, an anti-cxcl12/sdf-1 spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a phase iia study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383929/ https://www.ncbi.nlm.nih.gov/pubmed/28074071 http://dx.doi.org/10.1038/leu.2017.5 |
| work_keys_str_mv | AT ludwigh olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT weiselk olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT petruccimt olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT leleux olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT cafroam olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT garderetl olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT leitgebc olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT foar olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT greilr olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT yakoubaghai olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT zboralskid olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT vauleons olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT dummlert olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT beyerd olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT kruschinskia olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT rieckek olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT baumannm olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy AT engelhardtm olaptesedpegolananticxcl12sdf1spiegelmeraloneandwithbortezomibdexamethasoneinrelapsedrefractorymultiplemyelomaaphaseiiastudy |